Abstract
QUESTION Question: Do second-generation antipsychotics (SGAs) reduce extra-pyramidal side effects (EPS) compared with first-generation antipsychotics (FGAs)? Patients: 227 adults (18–65 years) with DSM-IV schizophrenia or schizophreniform, schizoaffective or delusional disorders....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
